255 related articles for article (PubMed ID: 28686671)
1. Assessment of circulating copy number variant detection for cancer screening.
Molparia B; Nichani E; Torkamani A
PLoS One; 2017; 12(7):e0180647. PubMed ID: 28686671
[TBL] [Abstract][Full Text] [Related]
2. A feasibility study of colorectal cancer diagnosis via circulating tumor DNA derived CNV detection.
Molparia B; Oliveira G; Wagner JL; Spencer EG; Torkamani A
PLoS One; 2018; 13(5):e0196826. PubMed ID: 29791457
[TBL] [Abstract][Full Text] [Related]
3. Nanotechnology Strategies for the Analysis of Circulating Tumor DNA: A Review.
Chen X; Wang L; Lou J
Med Sci Monit; 2020 Mar; 26():e921040. PubMed ID: 32200389
[TBL] [Abstract][Full Text] [Related]
4. Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer.
Cheng F; Su L; Qian C
Oncotarget; 2016 Jul; 7(30):48832-48841. PubMed ID: 27223063
[TBL] [Abstract][Full Text] [Related]
5. Genomic variations in plasma cell free DNA differentiate early stage lung cancers from normal controls.
Xia S; Huang CC; Le M; Dittmar R; Du M; Yuan T; Guo Y; Wang Y; Wang X; Tsai S; Suster S; Mackinnon AC; Wang L
Lung Cancer; 2015 Oct; 90(1):78-84. PubMed ID: 26233568
[TBL] [Abstract][Full Text] [Related]
6. Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review.
Merker JD; Oxnard GR; Compton C; Diehn M; Hurley P; Lazar AJ; Lindeman N; Lockwood CM; Rai AJ; Schilsky RL; Tsimberidou AM; Vasalos P; Billman BL; Oliver TK; Bruinooge SS; Hayes DF; Turner NC
J Clin Oncol; 2018 Jun; 36(16):1631-1641. PubMed ID: 29504847
[TBL] [Abstract][Full Text] [Related]
7. The feasibility of using mutation detection in ctDNA to assess tumor dynamics.
Yi X; Ma J; Guan Y; Chen R; Yang L; Xia X
Int J Cancer; 2017 Jun; 140(12):2642-2647. PubMed ID: 28124376
[TBL] [Abstract][Full Text] [Related]
8. Personalized Circulating Tumor DNA Biomarkers Dynamically Predict Treatment Response and Survival In Gynecologic Cancers.
Pereira E; Camacho-Vanegas O; Anand S; Sebra R; Catalina Camacho S; Garnar-Wortzel L; Nair N; Moshier E; Wooten M; Uzilov A; Chen R; Prasad-Hayes M; Zakashansky K; Beddoe AM; Schadt E; Dottino P; Martignetti JA
PLoS One; 2015; 10(12):e0145754. PubMed ID: 26717006
[TBL] [Abstract][Full Text] [Related]
9. Do circulating tumor cells, exosomes, and circulating tumor nucleic acids have clinical utility? A report of the association for molecular pathology.
Gold B; Cankovic M; Furtado LV; Meier F; Gocke CD
J Mol Diagn; 2015 May; 17(3):209-24. PubMed ID: 25908243
[TBL] [Abstract][Full Text] [Related]
10. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage.
Newman AM; Bratman SV; To J; Wynne JF; Eclov NC; Modlin LA; Liu CL; Neal JW; Wakelee HA; Merritt RE; Shrager JB; Loo BW; Alizadeh AA; Diehn M
Nat Med; 2014 May; 20(5):548-54. PubMed ID: 24705333
[TBL] [Abstract][Full Text] [Related]
11. Accuracy of analysis of cfDNA for detection of single nucleotide variants and copy number variants in breast cancer.
Yang X; Zhang K; Zhang C; Peng R; Sun C
BMC Cancer; 2019 May; 19(1):465. PubMed ID: 31101027
[TBL] [Abstract][Full Text] [Related]
12. Detection of incipient tumours by screening of circulating plasma DNA: hype or hope?
Lenaerts L; Tuveri S; Jatsenko T; Amant F; Vermeesch JR
Acta Clin Belg; 2020 Feb; 75(1):9-18. PubMed ID: 31578135
[No Abstract] [Full Text] [Related]
13. Quantitative analysis of the BRAF
Ashida A; Sakaizawa K; Mikoshiba A; Uhara H; Okuyama R
Int J Clin Oncol; 2016 Oct; 21(5):981-988. PubMed ID: 27041702
[TBL] [Abstract][Full Text] [Related]
14. Circulating tumor cells and circulating tumor DNA: What surgical oncologists need to know?
Cabel L; Proudhon C; Mariani P; Tzanis D; Beinse G; Bieche I; Pierga JY; Bidard FC
Eur J Surg Oncol; 2017 May; 43(5):949-962. PubMed ID: 28185687
[TBL] [Abstract][Full Text] [Related]
15. Genomewide copy number alteration screening of circulating plasma DNA: potential for the detection of incipient tumors.
Lenaerts L; Vandenberghe P; Brison N; Che H; Neofytou M; Verheecke M; Leemans L; Maggen C; Dewaele B; Dehaspe L; Vanderschueren S; Dierickx D; Vandecaveye V; Amant F; Vermeesch JR
Ann Oncol; 2019 Jan; 30(1):85-95. PubMed ID: 30371735
[TBL] [Abstract][Full Text] [Related]
16. A Targeted Q-PCR-Based Method for Point Mutation Testing by Analyzing Circulating DNA for Cancer Management Care.
Thierry AR
Methods Mol Biol; 2016; 1392():1-16. PubMed ID: 26843041
[TBL] [Abstract][Full Text] [Related]
17. Parallel Analyses of Somatic Mutations in Plasma Circulating Tumor DNA (ctDNA) and Matched Tumor Tissues in Early-Stage Breast Cancer.
Zhang X; Zhao W; Wei W; You Z; Ou X; Sun M; Yin Y; Tang X; Zhao Z; Hu C; Liu F; Deng J; Mao L; Zhou D; Ren Y; Li X; Zhang S; Liu C; Geng J; Yao G; Song B; Liu Y; Li D; Jiang Y; Chen Y; Zhao Y; Yu S; Pang D
Clin Cancer Res; 2019 Nov; 25(21):6546-6553. PubMed ID: 31350313
[TBL] [Abstract][Full Text] [Related]
18. Utility of circulating tumor DNA in cancer diagnostics with emphasis on early detection.
Fiala C; Diamandis EP
BMC Med; 2018 Oct; 16(1):166. PubMed ID: 30285732
[TBL] [Abstract][Full Text] [Related]
19. Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy.
Alix-Panabières C; Pantel K
Cancer Discov; 2016 May; 6(5):479-91. PubMed ID: 26969689
[TBL] [Abstract][Full Text] [Related]
20. Circulating tumour DNA (ctDNA) as a liquid biopsy for melanoma.
Calapre L; Warburton L; Millward M; Ziman M; Gray ES
Cancer Lett; 2017 Sep; 404():62-69. PubMed ID: 28687355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
